ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 136 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 4.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,567,380 | -42.1% | 483,499 | +3.8% | 0.00% | -100.0% |
Q2 2023 | $4,437,673 | +4.3% | 465,653 | +20.4% | 0.00% | 0.0% |
Q1 2023 | $4,255,471 | -25.3% | 386,861 | +0.5% | 0.00% | 0.0% |
Q4 2022 | $5,695,810 | -20.2% | 384,852 | +3.0% | 0.00% | -50.0% |
Q3 2022 | $7,141,000 | +6.4% | 373,701 | +18.6% | 0.00% | +100.0% |
Q2 2022 | $6,714,000 | +34.6% | 315,058 | +21.7% | 0.00% | 0.0% |
Q1 2022 | $4,987,000 | -10.9% | 258,937 | -4.1% | 0.00% | 0.0% |
Q4 2021 | $5,599,000 | -13.4% | 269,953 | -0.2% | 0.00% | 0.0% |
Q3 2021 | $6,463,000 | -18.4% | 270,519 | -6.8% | 0.00% | 0.0% |
Q2 2021 | $7,916,000 | +2.6% | 290,103 | +8.7% | 0.00% | 0.0% |
Q1 2021 | $7,719,000 | +14.2% | 266,818 | +11.1% | 0.00% | 0.0% |
Q4 2020 | $6,758,000 | +9.7% | 240,255 | +14.3% | 0.00% | 0.0% |
Q3 2020 | $6,162,000 | +58.8% | 210,268 | +63.8% | 0.00% | 0.0% |
Q2 2020 | $3,881,000 | +20.1% | 128,330 | +18.3% | 0.00% | 0.0% |
Q1 2020 | $3,232,000 | – | 108,459 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Frazier Life Sciences Management, L.P. | 8,684,232 | $165,956,000 | 12.78% |
Bain Capital Life Sciences Investors, LLC | 3,000,000 | $57,330,000 | 6.84% |
Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $10,874,000 | 3.97% |
Logos Global Management LP | 1,525,000 | $29,143,000 | 3.58% |
1492 Capital Management LLC | 178,320 | $3,408,000 | 2.45% |
Cormorant Asset Management, LP | 1,000,000 | $19,110,000 | 1.34% |
MPM BioImpact LLC | 257,185 | $4,915,000 | 1.16% |
Orbimed Advisors | 2,800,000 | $53,508,000 | 0.99% |
SECTORAL ASSET MANAGEMENT INC | 220,985 | $4,223,000 | 0.83% |
Rubric Capital Management LP | 472,047 | $9,021,000 | 0.45% |